Aligos Therapeutics, Inc. (NASDAQ:ALGS – Get Free Report) was the recipient of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 657,200 shares, a drop of 24.4% from the March 31st total of 868,800 shares. Based on an average daily volume of 388,300 shares, the days-to-cover ratio is presently 1.7 days.
Aligos Therapeutics Stock Down 4.4 %
Shares of ALGS stock opened at $0.78 on Friday. Aligos Therapeutics has a one year low of $0.54 and a one year high of $1.38. The stock has a fifty day moving average price of $0.91 and a 200 day moving average price of $0.76.
Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) last issued its earnings results on Tuesday, March 12th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.05. The firm had revenue of $2.68 million during the quarter, compared to analysts’ expectations of $3.20 million. Aligos Therapeutics had a negative return on equity of 116.41% and a negative net margin of 607.03%. On average, research analysts forecast that Aligos Therapeutics will post -0.83 EPS for the current fiscal year.
Institutional Inflows and Outflows
Aligos Therapeutics Company Profile
Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
See Also
- Five stocks we like better than Aligos Therapeutics
- Utilities Stocks Explained – How and Why to Invest in Utilities
- MarketBeat Week in Review – 4/22 – 4/26
- 3 Tickers Leading a Meme Stock Revival
- 3 Stocks Leading the U.S. Agriculture Comeback
- What is the Australian Securities Exchange (ASX)
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.